Literature DB >> 19064899

Postantibiotic effect of tigecycline against 14 gram-positive organisms.

G A Pankuch1, P C Appelbaum.   

Abstract

The in vitro postantibiotic effects (PAEs), postantibiotic sub-MIC effects (PA-SMEs), and sub-MIC effects of tigecycline were determined for 14 gram-positive and gram-negative organisms. The pneumococcal, staphylococcal, and enterococcal PAEs were 1.9 to 5.1, 2.9 to 5.7, and 3.9 to 6.1 h, respectively, and those for Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii were 1.1 to 5.0, 1.9 to 2.1, 1.7 to 1.8, 1.0 to 1.7, and 0.7 to 3 h, respectively. The PA-SMEs (four times the MIC) ranged from 6.7 to >11 h for gram-positive organisms and from 2.3 to >11.3 h for gram-negative organisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19064899      PMCID: PMC2630611          DOI: 10.1128/AAC.01122-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.

Authors:  Patricia A Bradford; D Tasha Weaver-Sands; Peter J Petersen
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

2.  The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

Authors:  Timothy Babinchak; Evelyn Ellis-Grosse; Nathalie Dartois; Gilbert M Rose; Evan Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

3.  The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Authors:  E J Ellis-Grosse; T Babinchak; N Dartois; G Rose; E Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

Review 4.  The post-antibiotic sub-MIC effect in vitro and in vivo.

Authors:  O Cars; I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

5.  In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors:  M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

Authors:  S J Projan
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

7.  In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.

Authors:  Thomas R Fritsche; Jeffrey T Kirby; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-07       Impact factor: 2.803

Review 8.  Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.

Authors:  W A Craig
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

9.  Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis.

Authors:  Agnès Lefort; Matthieu Lafaurie; Laurent Massias; Yolande Petegnief; Azzam Saleh-Mghir; Claudette Muller-Serieys; Dominique Le Guludec; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more
  4 in total

1.  In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes.

Authors:  Chunna Guo; Xiaoping Liao; Mingru Wang; Feng Wang; Chaoqun Yan; Xia Xiao; Jiang Sun; Yahong Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

2.  Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit.

Authors:  Berna Ozbek Celik; Emel Mataraci-Kara; Mesut Yilmaz
Journal:  Biomed Res Int       Date:  2014-10-28       Impact factor: 3.411

3.  Design and pharmacodynamics of recombinant NZ2114 histidine mutants with improved activity against methicillin-resistant Staphylococcus aureus.

Authors:  Huixian Chen; Ruoyu Mao; Da Teng; Xiumin Wang; Ya Hao; Xingjun Feng; Jianhua Wang
Journal:  AMB Express       Date:  2017-02-22       Impact factor: 3.298

4.  Antibacterial and immunomodulatory activities of insect defensins-DLP2 and DLP4 against multidrug-resistant Staphylococcus aureus.

Authors:  Zhanzhan Li; Ruoyu Mao; Da Teng; Ya Hao; Huixian Chen; Xiumin Wang; Xiao Wang; Na Yang; Jianhua Wang
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.